Relationship Between Body Mass Index and Insulin Resistance in Patients Treated with Second Generation Antipsychotic Agents

Overview

Journal J Psychiatr Res

Specialty Psychiatry

Date 2009 Dec 8

PMID 19962157

Citations 5

Authors

Sun H Kim

Lilla Nikolics

Fahim Abbasi

Cindy Lamendola

James Link

Gerald M Reaven

Steven Lindley

Affiliations

Soon will be listed here.

Abstract

Second generation antipsychotics (SGAs) can increase weight gain and weight-induced insulin resistance. Recent studies have suggested weight-independent effects of certain SGAs on insulin resistance; however the magnitude of these effects and the relationship between BMI and insulin resistance in patients on SGAs are not established. To evaluate, the relationship between body mass index (BMI) and insulin resistance in 54 patients being stably treated with olanzapine (n=19), risperidone (n=16), or aripiprazole (n=19) was compared with data from a large reference population (n=201) not on SGAs. Insulin resistance was directly quantified by measuring the steady-state plasma glucose (SSPG) concentration during the insulin suppression test. The relationship between BMI and SSPG was similar between the SGA (r=0.58) and the reference population (r=0.50). When SSPG was standardized based on expected values for the reference population, patients on olanzapine had a higher degree of insulin resistance (mean z-score+/-SD, 0.68+/-0.9) than expected for level of BMI compared with those on aripiprazole (-0.25+/-1) and risperidone (-0.3+/-0.9), F(2,51)=6.28 (p=0.004). Thus, olanzapine group was 0.76 SD above the reference population or in the 78 percentile for insulin resistance. SSPG was correlated with fasting plasma insulin concentration (0.78 (0.64-0.87), p<0.001) but not fasting glucose concentration (0.15 (-0.13-0.40), p=0.29). In conclusion, BMI contributes a quarter to a third of the variance in insulin resistance in the SGA population similar to the reference population. Olanzapine also appears to have an independent effect on insulin resistance that is above and beyond obesity.

Citing Articles

The Burden of Antipsychotic-Induced Weight Gain and Metabolic Syndrome in Children.

Libowitz M, Nurmi E Front Psychiatry. 2021; 12:623681.

PMID: 33776816 PMC: 7994286. DOI: 10.3389/fpsyt.2021.623681.

Association of obesity and treated hypertension and diabetes with cognitive ability in bipolar disorder and schizophrenia.

Depp C, Strassnig M, Mausbach B, Bowie C, Wolyniec P, Thornquist M Bipolar Disord. 2014; 16(4):422-31.

PMID: 24725166 PMC: 4047181. DOI: 10.1111/bdi.12200.

Anthropometric parameters as indicators of metabolic derangements in schizophrenia patients stabilized on olanzapine in an Indian rural population.

Rout J, Dasgupta A, Singh O, Banerjee U, Das B J Neurosci Rural Pract. 2012; 3(3):277-82.

PMID: 23188977 PMC: 3505316. DOI: 10.4103/0976-3147.102605.

Gender-dependent consequences of chronic olanzapine in the rat: effects on body weight, inflammatory, metabolic and microbiota parameters.

Davey K, OMahony S, Schellekens H, OSullivan O, Bienenstock J, Cotter P Psychopharmacology (Berl). 2012; 221(1):155-69.

PMID: 22234378 DOI: 10.1007/s00213-011-2555-2.

Relationship between insulin resistance and C-reactive protein in a patient population treated with second generation antipsychotic medications.

Kim S, Reaven G, Lindley S Int Clin Psychopharmacol. 2010; 26(1):43-7.

PMID: 20861740 PMC: 4570472. DOI: 10.1097/YIC.0b013e3283400cd3.

References

Reaven G . The insulin resistance syndrome. Curr Atheroscler Rep. 2003; 5(5):364-71. DOI: 10.1007/s11883-003-0007-0. View

Bogardus C, Lillioja S, Mott D, Hollenbeck C, Reaven G . Relationship between degree of obesity and in vivo insulin action in man. Am J Physiol. 1985; 248(3 Pt 1):E286-91. DOI: 10.1152/ajpendo.1985.248.3.E286. View

. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004; 27(2):596-601. DOI: 10.2337/diacare.27.2.596. View

Chintoh A, Mann S, Lam L, Lam C, Cohn T, Fletcher P . Insulin resistance and decreased glucose-stimulated insulin secretion after acute olanzapine administration. J Clin Psychopharmacol. 2008; 28(5):494-9. DOI: 10.1097/JCP.0b013e318184b4c5. View

Pei D, Jones C, Bhargava R, Chen Y, Reaven G . Evaluation of octreotide to assess insulin-mediated glucose disposal by the insulin suppression test. Diabetologia. 1994; 37(8):843-5. DOI: 10.1007/BF00404344. View

Gothelf D, Falk B, Singer P, Kairi M, Phillip M, Zigel L . Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine. Am J Psychiatry. 2002; 159(6):1055-7. DOI: 10.1176/appi.ajp.159.6.1055. View

Sowell M, Mukhopadhyay N, Cavazzoni P, Shankar S, Steinberg H, Breier A . Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or placebo. J Clin Endocrinol Metab. 2002; 87(6):2918-23. DOI: 10.1210/jcem.87.6.8599. View

Lieberman J, Stroup T, McEvoy J, Swartz M, Rosenheck R, Perkins D . Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005; 353(12):1209-23. DOI: 10.1056/NEJMoa051688. View

Choi S, DiSilvio B, Unangst J, Fernstrom J . Effect of chronic infusion of olanzapine and clozapine on food intake and body weight gain in male and female rats. Life Sci. 2007; 81(12):1024-30. PMC: 3998666. DOI: 10.1016/j.lfs.2007.08.009. View

10.

Sheehan D, Lecrubier Y, Sheehan K, Amorim P, Janavs J, Weiller E . The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1999; 59 Suppl 20:22-33;quiz 34-57. View

11.

Houseknecht K, Robertson A, Zavadoski W, Gibbs E, Johnson D, Rollema H . Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects. Neuropsychopharmacology. 2006; 32(2):289-97. DOI: 10.1038/sj.npp.1301209. View

12.

Sowell M, Mukhopadhyay N, Cavazzoni P, Carlson C, Mudaliar S, Chinnapongse S . Evaluation of insulin sensitivity in healthy volunteers treated with olanzapine, risperidone, or placebo: a prospective, randomized study using the two-step hyperinsulinemic, euglycemic clamp. J Clin Endocrinol Metab. 2003; 88(12):5875-80. DOI: 10.1210/jc.2002-021884. View

13.

Henderson D, Copeland P, Borba C, Daley T, Nguyen D, Cagliero E . Glucose metabolism in patients with schizophrenia treated with olanzapine or quetiapine: a frequently sampled intravenous glucose tolerance test and minimal model analysis. J Clin Psychiatry. 2006; 67(5):789-97. DOI: 10.4088/jcp.v67n0513. View

14.

Facchini F, Hua N, Abbasi F, Reaven G . Insulin resistance as a predictor of age-related diseases. J Clin Endocrinol Metab. 2001; 86(8):3574-8. DOI: 10.1210/jcem.86.8.7763. View

15.

Haupt D, Fahnestock P, Flavin K, Schweiger J, Stevens A, Hessler M . Adiposity and insulin sensitivity derived from intravenous glucose tolerance tests in antipsychotic-treated patients. Neuropsychopharmacology. 2007; 32(12):2561-9. DOI: 10.1038/sj.npp.1301392. View

16.

Kim S, Abbasi F, Reaven G . Impact of degree of obesity on surrogate estimates of insulin resistance. Diabetes Care. 2004; 27(8):1998-2002. DOI: 10.2337/diacare.27.8.1998. View

17.

Reaven G . All obese individuals are not created equal: insulin resistance is the major determinant of cardiovascular disease in overweight/obese individuals. Diab Vasc Dis Res. 2005; 2(3):105-12. DOI: 10.3132/dvdr.2005.017. View

18.

Chintoh A, Mann S, Lam T, Giacca A, Remington G . Insulin resistance following continuous, chronic olanzapine treatment: an animal model. Schizophr Res. 2008; 104(1-3):23-30. DOI: 10.1016/j.schres.2008.06.006. View

19.

McAuley K, Williams S, Mann J, Walker R, Lewis-Barned N, TEMPLE L . Diagnosing insulin resistance in the general population. Diabetes Care. 2001; 24(3):460-4. DOI: 10.2337/diacare.24.3.460. View

20.

Saad M, Anderson R, Laws A, Watanabe R, Kades W, Chen Y . A comparison between the minimal model and the glucose clamp in the assessment of insulin sensitivity across the spectrum of glucose tolerance. Insulin Resistance Atherosclerosis Study. Diabetes. 1994; 43(9):1114-21. DOI: 10.2337/diab.43.9.1114. View